Liver Transplantation: Information on allocation of livers, recurrent HCV after transplantation, treatment of HCV before and after liver transplantation, post transplantation disease progression, and long term outcomes after liver transplantation



o       526. The Impact of MELD Allocation Policy on Racial Disparities in Access to Liver Transplantation.

o       534. Race/Ethnicity and Geographic Disparities in Waitlisting and Waitlist Outcomes in the Post-MELD Era.

o       545. Racial Disparities in Patient Survivals After Pediatric Liver Transplantation. (Updated Nov 1)

o       548. Relationship between Recipient Race and Transplant Center as Predictors of Outcome following Liver Transplantation.

o       586. Liver Transplantation Trends and Survival in the Asian Population.



o       524. Hepatitis C Positive Liver Transplant Recipients who Receive Grafts from Donors with Hepatitis C Antibodies have Similar Outcomes to Hepatitis C Negative Donors. (Updated Nov 1)

o       540. Predictors of patient and graft survivals following orthotopic liver transplantation (OLT) in patients with HCV cirrhosis. (Updated Nov 1)

o       547. Wide Disparity in Substance Use Policies for Liver Transplant Candidates at U.S. Centers.

o       555. Outcomes and Resource Utilization during Hospitalization for Liver Transplantation in the United States and the impact of MELD: A Nationwide Study.

o       558. The duration of pre-transplant abstinence is an independent predictor of problem drinking post liver transplantation. (Updated Nov 1)

o       562. Outcomes of Liver Transplantation in Combined Hepatitis C and Hepatocellular Carcinoma Are Not Inferior to Hepatitis C Alone.

o       566. Health related quality of life predicts survival in liver transplant candidates.

o       596. Long Term Outcomes in Non-Heart Beating Donor Grafts in Liver Transplantation for Chronic Hepatitis C: no increase in HCV recurrence or graft loss.

o       602. Outcomes of Patients with Hepatitis C Undergoing Simultaneous Liver-Kidney Transplant vs. Liver Transplant Alone.

o       603. Evaluation of FIB-4 as a Marker of Fibrosis in HCV Infected Patients who Underwent Liver Transplantation.

o       606. Impact of donor age on SVR in liver transplant (LT) recipients treated with pegIFN-ribavirin.

o       608. Donor age affects response to antiviral therapy in patients with recurrent hepatitis C following liver transplantation.

o       620. Short term maintenance steroids and azathioprine and absence of hepatitis flares are associated with improved patient and graft survival of HCV after Liver Transplantation.

o       621. Excellent 5-year overall survival in patients with HBV-related cirrhosis undergoing liver transplantation for hepatocellular carcinoma.

o       624. Survival after Orthotopic Liver Transplantation (OLT) for HCV Cirrhosis has not improved in the Model for End-stage Liver Disease (MELD) era.

o       628. Incidence and Prognostic Significance of Immune Markers in Patients with HCV Undergoing Liver Transplantation.

o       633. Obesity, Diabetes, and Smoking are Important Determinants of Resource Utilization in Liver Resection: A Multicenter Analysis of 1029 Patients. (Updated Nov 1)

o       643. Is the Mayo Post-operative Mortality Risk Prediction Model applicable to Asian Cirrhotic Patients?


        HCV Recurrence

o       601. Incidence of Acute Cellular Rejection During Interferon-based Therapy for Recurrent Hepatitis C following Liver Transplantation: A Retrospective Study.

o       609. A Clinical Characterization of Patients with the Cholestatic Variant of Recurrent Hepatitis C Following Liver Transplantation.

o       610. Outcome of Interferon (IFN)-Based Antiviral Therapy in African-Americans (AA) With Recurrent Hepatitis C Virus (HCV) Disease Following Liver Transplantation (LT).

o       613. Serum Markers of Liver Fibrosis Identify Patients with Mild and Severe Hepatitis C Recurrence Six Months after Liver Transplantation.

o       614. Early virological response and absence of diabetes are associated with sustained virological response to hepatitis C treatment after liver transplantation in patients with cyclosporine A based immunosuppression.

o       615. Survival and risk factors associated with severe fibrosis in patients with recurrent hepatitis C.

o       617. The impact of antiviral therapy on fibrosis progression in HCV recurrence after liver transplantation (LT).

o       623. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: Systematic review and meta-analysis of prospective controlled studies.

o       626. PegIFN-ribavirin for recurrent hepatitis C: worse efficacy in recent years.

o       627. Severe HCV infection recurence on the liver graft of patient transplanted for HCV related cirrhosis : Is retransplantation feasible?

o       1268. Prospective randomized study of antiviral therapy post-transplantation: effect of the type of pegylated IFN and baseline immunosuppression. (Updated Nov 3)

o       1318. Standard or pegylated interferon with or without ribavirin treatment of hepatitis C after liver transplant: a meta-analysis.



o       604. Incidence and outcomes of acute hepatitis E in a liver transplant unit.

o       607. Lack of evidence for chronic Hepatitis E as a major cause of graft hepatitis in liver transplant recipients.


        HIV/HCV Coinfection

o       616. A Description of fibrosing cholestatic hepatitis after liver transplantation (LT) in HIV-HCV coinfected patients.


        Live Liver Donation

o       618. Long-Term Outcome in HCV Recipients of Live Donor Liver Transplants: Histological and Clinical follow-up.

o       629. A high MELD score is not a contraindication for right lobe adult living donor liver transplantation.

o       631. Minimally invasive donor hepatectomy in adult-to-adult living donor liver transplantation: Single center experience.